Cargando…

Co-activation: its association with weakness and specific neurological pathology

BACKGROUND: Net agonist muscle strength is in part determined by the degree of antagonist co-activation. The level of co-activation might vary in different neurological disorders causing weakness or might vary with agonist strength. AIM: This study investigated whether antagonist co-activation chang...

Descripción completa

Detalles Bibliográficos
Autores principales: Busse, Monica E, Wiles, Charles M, van Deursen, Robert WM
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665451/
https://www.ncbi.nlm.nih.gov/pubmed/17116259
http://dx.doi.org/10.1186/1743-0003-3-26
_version_ 1782131106004336640
author Busse, Monica E
Wiles, Charles M
van Deursen, Robert WM
author_facet Busse, Monica E
Wiles, Charles M
van Deursen, Robert WM
author_sort Busse, Monica E
collection PubMed
description BACKGROUND: Net agonist muscle strength is in part determined by the degree of antagonist co-activation. The level of co-activation might vary in different neurological disorders causing weakness or might vary with agonist strength. AIM: This study investigated whether antagonist co-activation changed a) with the degree of muscle weakness and b) with the nature of the neurological lesion causing weakness. METHODS: Measures of isometric quadriceps and hamstrings strength were obtained. Antagonist (hamstring) co-activation during knee extension was calculated as a ratio of hamstrings over quadriceps activity both during an isometric and during a functional sit to stand (STS) task (using kinematics) in groups of patients with extrapyramidal (n = 15), upper motor neuron (UMN) (n = 12), lower motor neuron (LMN) with (n = 18) or without (n = 12) sensory loss, primary muscle or neuromuscular junction disorder (n = 17) and in healthy matched controls (n = 32). Independent t-tests or Mann Witney U tests were used to compare between the groups. Correlations between variables were also investigated. RESULTS: In healthy subjects mean (SD) co-activation of hamstrings during isometric knee extension was 11.8 (6.2)% and during STS was 20.5 (12.9)%. In patients, co-activation ranged from 7 to 17% during isometric knee extension and 15 to 25% during STS. Only the extrapyramidal group had lower co-activation levels than healthy matched controls (p < 0.05). Agonist isometric muscle strength and co-activation correlated only in muscle disease (r = -0.6, p < 0.05) and during STS in UMN disorders (r = -0.7, p < 0.5). CONCLUSION: It is concluded that antagonist co-activation does not systematically vary with the site of neurological pathology when compared to healthy matched controls or, in most patient groups, with strength. The lower co-activation levels found in the extrapyramidal group require confirmation and further investigation. Co-activation may be relevant to individuals with muscle weakness. Within patient serial studies in the presence of changing muscle strength may help to understand these relationships more clearly.
format Text
id pubmed-1665451
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-16654512006-12-05 Co-activation: its association with weakness and specific neurological pathology Busse, Monica E Wiles, Charles M van Deursen, Robert WM J Neuroengineering Rehabil Research BACKGROUND: Net agonist muscle strength is in part determined by the degree of antagonist co-activation. The level of co-activation might vary in different neurological disorders causing weakness or might vary with agonist strength. AIM: This study investigated whether antagonist co-activation changed a) with the degree of muscle weakness and b) with the nature of the neurological lesion causing weakness. METHODS: Measures of isometric quadriceps and hamstrings strength were obtained. Antagonist (hamstring) co-activation during knee extension was calculated as a ratio of hamstrings over quadriceps activity both during an isometric and during a functional sit to stand (STS) task (using kinematics) in groups of patients with extrapyramidal (n = 15), upper motor neuron (UMN) (n = 12), lower motor neuron (LMN) with (n = 18) or without (n = 12) sensory loss, primary muscle or neuromuscular junction disorder (n = 17) and in healthy matched controls (n = 32). Independent t-tests or Mann Witney U tests were used to compare between the groups. Correlations between variables were also investigated. RESULTS: In healthy subjects mean (SD) co-activation of hamstrings during isometric knee extension was 11.8 (6.2)% and during STS was 20.5 (12.9)%. In patients, co-activation ranged from 7 to 17% during isometric knee extension and 15 to 25% during STS. Only the extrapyramidal group had lower co-activation levels than healthy matched controls (p < 0.05). Agonist isometric muscle strength and co-activation correlated only in muscle disease (r = -0.6, p < 0.05) and during STS in UMN disorders (r = -0.7, p < 0.5). CONCLUSION: It is concluded that antagonist co-activation does not systematically vary with the site of neurological pathology when compared to healthy matched controls or, in most patient groups, with strength. The lower co-activation levels found in the extrapyramidal group require confirmation and further investigation. Co-activation may be relevant to individuals with muscle weakness. Within patient serial studies in the presence of changing muscle strength may help to understand these relationships more clearly. BioMed Central 2006-11-20 /pmc/articles/PMC1665451/ /pubmed/17116259 http://dx.doi.org/10.1186/1743-0003-3-26 Text en Copyright © 2006 Busse et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Busse, Monica E
Wiles, Charles M
van Deursen, Robert WM
Co-activation: its association with weakness and specific neurological pathology
title Co-activation: its association with weakness and specific neurological pathology
title_full Co-activation: its association with weakness and specific neurological pathology
title_fullStr Co-activation: its association with weakness and specific neurological pathology
title_full_unstemmed Co-activation: its association with weakness and specific neurological pathology
title_short Co-activation: its association with weakness and specific neurological pathology
title_sort co-activation: its association with weakness and specific neurological pathology
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665451/
https://www.ncbi.nlm.nih.gov/pubmed/17116259
http://dx.doi.org/10.1186/1743-0003-3-26
work_keys_str_mv AT bussemonicae coactivationitsassociationwithweaknessandspecificneurologicalpathology
AT wilescharlesm coactivationitsassociationwithweaknessandspecificneurologicalpathology
AT vandeursenrobertwm coactivationitsassociationwithweaknessandspecificneurologicalpathology